<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="2491">
  <stage>Registered</stage>
  <submitdate>15/09/2009</submitdate>
  <approvaldate>15/09/2009</approvaldate>
  <nctid>NCT00978341</nctid>
  <trial_identification>
    <studytitle>Study to Determine if a Reduction in Pain Can be Measured in Spinal Cord Injured Patients Using a New Study Design</studytitle>
    <scientifictitle>A Methodology Study to Assess the Ability of a Randomised, Double Blind, Placebo Controlled, Crossover Trial Design in Spinal Cord Injury Patients With Pain of Neuropathic Origin to Detect Improvement in Pain Endpoints Using Pregabalin as a Benchmark Compound</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>A0081141</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Spinal Cord Injuries</healthcondition>
    <conditioncode>
      <conditioncode1>Injuries and Accidents</conditioncode1>
      <conditioncode2>Fractures</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Injuries and Accidents</conditioncode1>
      <conditioncode2>Other injuries and accidents</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Neurological</conditioncode1>
      <conditioncode2>Other neurological disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Pregabalin
Treatment: drugs - Placebo for pregabalin

Experimental: Pregabalin - 

Other: Placebo - 


Treatment: drugs: Pregabalin
Pregabalin 150mg capsules BID for 7.5 days

Treatment: drugs: Placebo for pregabalin
Placebo capsules BID for 7.5 days

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Present Pain Intensity Score</outcome>
      <timepoint>Day 1: 0 (pre-dose), 0.5, 1, 2, 3, 4, 5, 6, 8, 10, and 12 hours (post-dose); Day 8: 0 (pre-dose), 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, and 48 hours (post-dose)</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Daily Pain Score</outcome>
      <timepoint>Predose: Daily from 7 days before Visit 2 (start of Intervention 1) until the morning of Visit 5 (end of Intervention 2)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Dynamic Allodynia Area</outcome>
      <timepoint>Screening, Days 1 &amp; 8: 0 (pre-dose) &amp; 4 hours post-dose,</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Dynamic Allodynia Pain Score</outcome>
      <timepoint>Screening, Days 1 &amp; 8: 0 (pre-dose), 0.5, 1, 2, 3, 4, 5, and 6 hours post-dose</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Punctate Allodynia Area</outcome>
      <timepoint>Screening, Days 1 &amp; 8: 0 (pre-dose) and 4 hours post-dose</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Mechanical Pain Sensitivity Stimulus-Response Function</outcome>
      <timepoint>Screening, Days 1 &amp; 8: 0 (pre-dose), &amp; 2, 4, and 6 hours post-dose</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Neuropathic Pain Symptom Inventory (NPSI)</outcome>
      <timepoint>Prior to morning dosing on Day 1 and prior to discharge on Day 8 for each period.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Pharmacokinetic Evaluations of Pregabalin</outcome>
      <timepoint>Day 1: 0 (pre-dose), 0.5, 1, 2, and 6 hours post-dose; Day 8: 0 (pre-dose), 1, 4, &amp; 6 hours post-dose</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  subjects who are outpatients or inpatients

          -  written informed consent obtained (signed by the subject or the subject's legally
             acceptable representative)

          -  traumatic spinal cord injury of at least 1 year duration with a nonprogressive, i.e.,
             chronic, stage of at least 6 months duration

          -  At-level neuropathic pain: spontaneous or evoked pain with neuropathic features
             (sharp, shooting, electric or burning pain sensation) in the region of sensory
             disturbance in a segmental pattern and located within two dermatomes above or below
             the level of spinal cord injury

          -  Below-level neuropathic pain: spontaneous or evoked pain with neuropathic features
             (sharp, shooting, electric or burning pain sensation) in the region of sensory
             disturbance located at least three dermatomes below the level of spinal cord injury</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>70</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  spinal cord injury (subjects with central pain and musculoskeletal pain must be able
             to make a distinction between the two)

          -  subjects who have previously not responded to 300 mg/day pregabalin: a non-responder
             is defined as a subject who has a reduction in pain score of less than 30% from
             baseline</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose />
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Crossover</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2 />
    <masking3 />
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate />
    <actualstartdate>1/02/2007</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>15</actualsamplesize>
    <recruitmentstatus>Terminated</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/10/2008</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,VIC</recruitmentstate>
    <hospital>Pfizer Investigational Site - Randwick</hospital>
    <hospital>Pfizer Investigational Site - St Leonards</hospital>
    <hospital>Pfizer Investigational Site - Warrawong</hospital>
    <hospital>Pfizer Investigational Site - Heidelberg</hospital>
    <postcode>2031 - Randwick</postcode>
    <postcode>2065 - St Leonards</postcode>
    <postcode>2502 - Warrawong</postcode>
    <postcode>3084 - Heidelberg</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Pfizer</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The study is designed to assess if spinal cord injury patients have reduced pain after taking
      either pregabalin or placebo in a cross over design. Patients had either pain at the level of
      their injury or below the level of their injury.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00978341</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Pfizer CT.gov Call Center</name>
      <address>Pfizer</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>